HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NGOs, ECHA Wrangle Over Agency's Responsibilities Under REACH

This article was originally published in The Rose Sheet

Executive Summary

European NGOs say chemicals industry and its influence over the European Chemicals Agency are undermining the efforts of the REACH chemicals law, though ECHA claims the NGOs fail to understand the agency’s responsibilities.

You may also be interested in...



REACH Progress Report Cites Familiar Problems, With Some Improvement

ECHA sees some improvement in REACH dossiers, but familiar problems remain, according to its 2012 Progress Report. The agency notes that 2012 was a “crucial” year as it completed its examination of all testing proposals received for the first REACH deadline in 2010.

ECHA Targets Registration Errors As REACH Deadline Looms

With the next REACH deadline in sight, ECHA announces that it is taking action against registrants that falsely register substances as intermediates. The agency also is making a final push to identify lead registrants for unclaimed substances and offering improved IT to help support the development of quality dossiers.

EC Looks To Reduce REACH Burden For Smaller Firms

REACH is already making an impact on chemicals safety in Europe, according to a report from the European Commission. However, improvements can be made, including fee reductions for small and middle-sized enterprises, the EC says.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel